Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 6/20 | 0.44 |
| ▸ | FABP3 | P05413 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540789 | 0.82 | NPC1 (0.66) | PLA2G10DYRK1ANPC1RAB9AMAPT | |
| SCHEMBL6181841 | 0.80 | CTNNB1 (0.52) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL24499935 | 0.75 | PLA2G10 (0.59) | PLA2G10DYRK1ANPC1RAB9AMAPT | |
| SCHEMBL1328163 | 0.75 | PLA2G10 (1.00) | PLA2G10NPC1RAB9AMAPTCLK1 | |
| SCHEMBL15999120 | 0.73 | PLA2G10 (0.56) | PLA2G10DYRK1ANPC1RAB9AFABP4 | |
| SCHEMBL3001737 | 0.72 | BCL2L1 (0.55) | ALDH1A1 | |
| SCHEMBL1675690 | 0.72 | TTR (0.56) | PLA2G10DYRK1ANPC1RAB9AMAPT | |
| SCHEMBL1675401 | 0.72 | HDAC6 (0.59) | PLA2G10DYRK1ANPC1RAB9AMAPT | |
| SCHEMBL2873897 | 0.72 | KMO (0.54) | ALDH1A1 | |
| SCHEMBL12521272 | 0.72 | HDAC1 (0.72) | SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| US-9580438-B2 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | 4SC DISCOVERY GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-9580438-B2 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | 4SC DISCOVERY GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-9580438-B2 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | 4SC DISCOVERY GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-20150158878-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158878-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158878-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | CNKSR1, TYK2, ERBB2 | PLA2G10 4639/4885DYRK1A 324/4885NPC1 3777/4885 |
| US-20150158878-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | CHUK, KYNU, BLK | PLA2G10 3441/4885DYRK1A 181/4885NPC1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.